In this session, experts from Columbia University Herbert Irving Comprehensive Cancer Center will share updates in the treatment of acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL), including newly approved therapies and treatment options such as cell therapies. In addition, issues in allogeneic transplant for AML will be discussed, including strategies like micro-transplant and new approaches for GVHD treatment. New directions in treatment in terms of ongoing clinical trials in AML and ALL will also be shared.
Target audience – medical oncologists, trainees, other allied health professionals.
Updates on the Treatment of AML
Joseph G. Jurcic, MD, Professor of Medicine at CUMC; Director, Hematologic Malignancies Section, Columbia University Vagelos College of Physicians and Surgeons
Issues in Allogeneic Transplant for AML
Markus Y. Mapara, MD, PhD, Professor of Medicine, Columbia University Vagelos College of Physicians and Surgeons
New Approaches for ALL
Andrew Lipsky, MD, Assistant Professor of Medicine at CUMC, Columbia University Vagelos College of Physicians and Surgeons
Cell Therapies for ALL + AML
Ran Reshef, MD, Associate Professor of Medicine at CUMC, Columbia University Vagelos College of Physicians and Surgeons
Upon conclusion of this activity, participants will be better able to:
Describe promising new therapies for AML/ALL
Discuss principles of cell therapies and transplant and when the therapies can be utilized
Describe a patient journey from diagnosis to end of treatment
